Доступ предоставлен для: Guest
Critical Reviews™ in Oncogenesis
Главный редактор: Benjamin Bonavida (open in a new tab)

Выходит 4 номеров в год

ISSN Печать: 0893-9675

ISSN Онлайн: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

The ABL Genes in Normal and Abnormal Cell Development

Том 7, Выпуск 1-2, 1996, pp. 33-48
DOI: 10.1615/CritRevOncog.v7.i1-2.30
Get accessGet access

Краткое описание

Genetic alteration of the c-abl protooncogene has led to abnormal cellular development, primarily within the hemopoietic system. Different forms of oncogenic alteration have variations in biological strength for cellular transformation. The abnormal Abl oncoproteins are known to suppress apoptosis, which may be the basis for causing leukemia development. However, recent evidence also shows that c-abl proto-oncoprotein can inhibit apoptosis. Expression of the Abl oncoprotein in hemopoietic stem cells (HSCs) also results in alteration in the expression of certain cell surface molecules such that the interaction between HSCs and their marrow stroma microenvironment has become abnormal. The basis for the genetic alteration of the c-abl protooncogene in patients with chronic myelogenous leukemia may or may not be due to genetic imprinting.

ЦИТИРОВАНО В
  1. Keller-v.Amsberg Gunhild, Brümmendorf Tim H, Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia, Expert Review of Anticancer Therapy, 12, 9, 2012. Crossref

  2. Naz Rajesh, c-Abl proto-oncoprotein is expressed and tyrosine phosphorylated in human sperm cell, Molecular Reproduction and Development, 51, 2, 1998. Crossref

  3. Keller Gunhild, Schafhausen Philippe, Brummendorf Tim H, Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia, Expert Review of Hematology, 2, 5, 2009. Crossref

  4. Niyazi Maynur, Niyazi Maynur, Ghazizadeh Mohammad, Konishi Hideki, Kawanami Oichi, Sugisaki Yuichi, Araki Tsutomu, Expression of p73 and c-Abl Proteins in Human Ovarian Carcinomas., Journal of Nippon Medical School, 70, 3, 2003. Crossref

  5. Ashar Hena R., Tkachenko Alexei, Shah Pritesh, Chada Kiran, HMGA2 is expressed in an allele-specific manner in human lipomas, Cancer Genetics and Cytogenetics, 143, 2, 2003. Crossref

  6. Epstein Franklin H., Faderl Stefan, Talpaz Moshe, Estrov Zeev, O'Brien Susan, Kurzrock Razelle, Kantarjian Hagop M., The Biology of Chronic Myeloid Leukemia, New England Journal of Medicine, 341, 3, 1999. Crossref

  7. Keller Gunhild, Schafhausen Philippe, Brümmendorf Tim H., Bosutinib, in Small Molecules in Oncology, 184, 2010. Crossref

  8. O'Donovan M., Russell J. M., O'Leary J. J., Gillan J. A., Lawler M. P., Gaffney E. F., Abl expression, tumour grade, and apoptosis in chondrosarcoma, Molecular Pathology, 52, 6, 1999. Crossref

  9. Cao Ming-Yu, Lee Yoon, Feng Ning-Ping, Al-Qawasmeh Raed A., Viau Stéphane, Gu Xiao-Ping, Lau Leo, Jin Hongnan, Wang Ming, Vassilakos Aikaterini, Wright Jim A., Young Aiping H., NC381, a Novel Anticancer Agent, Arrests the Cell Cycle in G0-G1 and Inhibits Lung Tumor Cell Growth in Vitro and in Vivo, Journal of Pharmacology and Experimental Therapeutics, 308, 2, 2004. Crossref

  10. Le Quan, Daniel Rene, Chung Siu-Wah, Kang Anthony D., Eisenstein Toby K., Sultzer Barnet M., Simpkins Henry, Wong Peter M. C., Involvement of C-Abl Tyrosine Kinase in Lipopolysaccharide- Induced Macrophage Activation, The Journal of Immunology, 160, 7, 1998. Crossref

Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции Цены и условия подписки Begell House Контакты Language English 中文 Русский Português German French Spain